Release Date: March 5, 2009
BUFFALO, N.Y. -- An antibody with the potential to stop breast cancer in its path. A nanoparticle that can address a side effect of the treatment that hemophiliacs cannot live without. A "quantum dot" with the potential to treat cancer or harvest the power of the sun. An air purifier that kills the world's nastiest toxins.
No, they're not the stuff of science fiction.
These are some of the new inventions that were patented in 2008 by University at Buffalo researchers, a year that has seen the number of UB patents more than double from nine in 2007 to 21 last year.
More than 40 of these UB researchers were honored for their efforts to bring their research out of the lab and into the marketplace at the UB Inventors and Entrepreneurs Reception held March 5 in the Center for Tomorrow on the UB North (Amherst) Campus.
The reception also honored 11 UB technologies that were licensed to industry and the three most recent "graduates" of UB's Technology Incubator.
"The jump we saw this year in our patent activity is a testament to the intense and growing commitment we are seeing among our scientist-entrepreneurs, who increasingly seek ways to get their scientific advances out into society," said Robert J. Genco, vice provost and director of the UB Office of Science, Technology Transfer and Economic Outreach (STOR), which co-sponsored the event with the UB Office of the Vice President for Research.
"They know that the most important scientific discovery in the world may provide little value to society if it goes no further than a journal publication," he continued. "Today, UB is honoring its professors who have taken the critical steps toward using their scientific and technological expertise to address some of the world's most profound problems."
Genco and Kenneth M. Tramposch, associate vice president for research, addressed the inventors. President John B.Simpson and Provost Satish K. Tripathi also congratulated the inventors.
Some of the newly patented inventions are:
-- An antibody with the potential to stop breast cancer metastasis. "The monoclonal antibody we developed has been shown to extend significantly the survival of mice with human breast-cancer tumors and to inhibit the cancer's spread to the lungs in the animals by more than 50 percent," said lead investigator Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the UB School of Medicine and Biomedical Sciences.
-- The nanoparticle that treats hemophiliac patients who develop resistance to Factor VIII. "Our multifunctional, lipid nanoparticle improves the safety and efficacy of the protein by multiple mechanisms, improving stability of the protein, altering the immune response and making the particle stay in the blood longer," said lead investigator Sathy Balu-Iyer, Pharm.D., associate professor of pharmaceutical sciences in the UB School of Pharmacy and Pharmaceutical Sciences.
-- A quantum dot with the potential to treat cancer or harness solar energy. "Our process for synthesizing these silicon nanoparticles makes them potentially useful for various applications, including biological imaging and diagnostics, solar cells and light-emitting diodes," said Mark T. Swihart, UB associate professor of chemical and biological engineering in the School of Engineering and Applied Sciences and lead investigator.
-- An air sterilizer that kills every biological agent it meets. "The BioBlower can rapidly and continuously kill airborne biological pathogens, such as anthrax, and it has demonstrated the ability to eradicate other airborne pathogens, such as avian flu, SARS and influenza viruses," said James F. Garvey, Ph.D., UB professor of chemistry in the College of Arts and Sciences and lead investigator.
Also presented at the reception was the 2008 UB Entrepreneurial Spirit Award recognizing researchers who founded a company to license a UB technology. This year, it was presented to Bradley P. Fuhrman, M.D., professor of pediatrics and anesthesiology in the UB School of Medicine and Biomedical Sciences and chief of critical care at Women & Children's Hospital of Buffalo, and Mark Dowhy, director of the Pediatric Critical Care Laboratory in the UB Department of Pediatrics.
The invention was licensed from UB to Medical Conservation Devices (MCD) of Buffalo, located in UB's New York State Center of Excellence in Bioinformatics and Life Sciences. Fuhrman and Dowhy are founding partners in MCD, which is raising funds to further develop the prototype for FDA medical-device evaluation.
The event also will honor the three "graduates" of the UB Technology Incubator, which have now expanded into their own space. They are:
-- Absolute Energy, moving to Grand Island, a complete Energy Management Services and IT sourcing partner;
-- Lynx Technologies, moving to Grand Island, provides companies managing large networking computing environments with high-availability, high-reliability systems;
-- Integral Information Systems, moving to Buffalo, a developer of advanced analytical software and decision support systems for health care providers.
The University at Buffalo is a premier research-intensive public university, a flagship institution in the State University of New York system and its largest and most comprehensive campus. UB's more than 28,000 students pursue their academic interests through more than 300 undergraduate, graduate and professional degree programs. Founded in 1846, the University at Buffalo is a member of the Association of American Universities.
Get our news in your favorite channels. >> details